BLR&D Research Career Scientist Award Application

BLR

基本信息

项目摘要

The main focus of our research is to investigate the mechanism of development and progression of diabetic nephropathy (DN). Diabetes is prevalent in the people aged 20 years and older. The demographic of veterans population falls in this age group. In the US, diabetes represents the 6th leading cause of death; however, diabetes as a cause of death is underreported. Nearly 50% of the patients with diabetes develop nephropathy. A recent study demonstrated that diabetic patients with kidney disease had 87% higher risk of cardiovascular mortality when compared with those without kidney disease. The early pathologic changes in DN involve renal especially glomerular hypertrophy and expansion of matrix proteins such as collagen, fibronectin and laminin. My laboratory studies the signal transduction mechanisms that lead to the progression of DN. To test our concepts, we use both renal cells (glomerular mesangial and proximal tubular epithelial cells) in culture and mouse and rat models of diabetes. Since many pathologic effects of hyperglycemia are mediated by transforming growth factor-β (TGFβ), we investigate the signaling mechanisms of this cytokine in mesangial and proximal tubular epithelial cells. We discovered that the expression of tumor suppressor protein PTEN (phosphatase and tensin homolog deleted in chromosome 10) is reduced in the diabetic kidney and in renal cells cultured in the presence of high glucose or TGFβ. In recent years, we have extensively investigated the mechanism of PTEN downregulation in renal cells and in kidneys of diabetic rodents. The results showed the involvement of TGFβ in high glucose-induced suppression of PTEN levels in renal cells. Our results for the first time demonstrated the role of microRNA (miR)-21, miR-26 and miR-214 in the inhibition of PTEN expression in the diabetic milieu. These studies opened the door to the novel application of anti-microRNA therapy for DN. More recently, we extended these studies to include the role of mTOR (mechanistic target of rapamycin) complexes 1 and 2 in diabetic kidney disease. We provided the first evidence for the requirement of inactivation of the exclusive PRAS40 subunit of mTOR complex 1 for glomerular mesangial cell hypertrophy, a pathologic feature of DN. Together with other VA investigators, we showed that rapamycin ameliorated the renal pathologies in diabetic mice. However, rapamycin-mediated complete inhibition of mTOR activity may cause deleterious clinical outcome. In fact, loss of mTORC1 in proximal tubular epithelial cells of mice induces progressive fibrosis. Therefore, more recently we have focused on a novel protein, called deptor, which is a component of both mTOR complexes 1 and 2. In fact, deptor is an endogenous inhibitor of mTOR activity. For the first time, we showed that the renal expression of deptor was significantly reduced in humans with diabetes and in diabetic rodents and that this reduction contributed to the increased mTOR activity. In cultured mesangial and proximal tubular epithelial cells incubated with high glucose, the expression of deptor was significantly reduced, which resulted in sustained activation of both mTORC1 and mTORC2. Thus, it is important to study the mechanisms of deptor downregulation by hyperglycemia. We are currently investigating the epigenetic, post-transcriptional and post-translational mechanisms of deptor reduction in diabetic kidney disease. Furthermore, recent studies have demonstrated a strong correlation between diabetes and renal cell carcinoma (RCC). Also, the incidence of RCC increases after 30 years of age and peaks at the 6th decades, which fall in the demographic of veterans population. We showed that downregulation of PTEN by increased expression of specific microRNAs contributes to the proliferation and invasion of renal carcinoma cells. Thus, the goal of our studies is to investigate the molecular mechanisms of the progression of diabetic nephropathy and RCC, and identify signaling molecules that can be targeted by small molecular drugs and anti-microRNA based therapies.
我们研究的主要重点是研究发展和发展的机理 糖尿病性肾病(DN)。糖尿病在20岁及以上的人群中普遍存在。人群的 退伍军人人口属于这个年龄段。在美国,糖尿病代表死亡的第六个主要原因。 但是,糖尿病是死亡原因的报道不足。近50%的糖尿病患者发展 肾病。最近的一项研究表明,患有肾脏疾病的糖尿病患者的风险高87% 与没有肾脏疾病的患者相比,心血管死亡率。早期的病理变化 DN特别涉及肾小球肥大和基质蛋白(例如胶原蛋白)的扩展 纤连蛋白和层粘连蛋白。我的实验室研究导致进展的信号转导机制 Dn。为了测试我们的概念,我们使用肾细胞(肾小球肾小球和近端管状上皮 细胞)在糖尿病的培养和小鼠模型中。由于高血糖的许多病理影响是 通过转化生长因子-β(TGFβ)介导的,我们研究了该细胞因子在 膜和近端结节上皮细胞。我们发现肿瘤抑制蛋白的表达 糖尿病肾脏和在中降低了PTEN(磷酸酶和tensin同源物的缺失)和在 在高葡萄糖或TGFβ存在下培养的肾细胞。近年来,我们已经进行了广泛的研究 肾细胞和糖尿病啮齿动物肾脏中PTEN下调的机制。结果表明 TGFβ参与肾细胞中葡萄糖诱导的PTEN水平的抑制。我们的结果 第一次证明了microRNA(miR)-21,miR-26和miR-214在抑制PTEN中的作用 在糖尿病环境中的表达。这些研究为反微洋的新应用打开了大门 DN的治疗。最近,我们扩展了这些研究以包括MTOR的作用( 雷帕霉素)在糖尿病肾脏疾病中1和2。我们提供了要求的第一个证据 肾小球肾小球细胞肥大的MTOR复合物1的独家PRAS40亚基的失活, DN的病理特征。与其他VA调查人员一起,我们表明雷帕霉素改善了 糖尿病小鼠的肾脏病理。但是,雷帕霉素介导的MTOR活性的完全抑制可能 引起微妙的临床结果。实际上,小鼠近端肾小管上皮细胞中MTORC1的丧失会影响 进行性纤维化。因此,最近我们专注于一种新型蛋白质,称为Depoyer,这是一个 MTOR复合物1和2的成分。实际上,Deptor是MTOR活性的内源性抑制剂。为了 第一次,我们表明糖尿病人类的肾脏表达显着降低 在糖尿病啮齿动物中,这种还原有助于增加MTOR活性。在文化中 与高葡萄糖一起孵育的介膜和近端结节上皮细胞,Deptor的表达为 显着降低,导致MTORC1和MTORC2持续激活。那是 重要的是研究高血糖下调的部署机制。我们目前正在调查 糖尿病肾脏中部署的表观遗传学,转录后和翻译后的机制 疾病。此外,最近的研究表明糖尿病与肾细胞之间存在很强的相关性 癌(RCC)。同样,RCC的事件在30岁时增加,在6年代达到高峰, 这落在退伍军人人口的人口中。我们表明,通过增加PTEN的下调 特定microRNA的表达有助于肾癌细胞的增殖和侵袭。 这是我们研究的目的是研究糖尿病进展的分子机制 肾病和RCC,并鉴定可以由小分子药物靶向的信号分子和 基于抗微菌的疗法。

项目成果

期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Tyrosines-740/751 of PDGFRβ contribute to the activation of Akt/Hif1α/TGFβ nexus to drive high glucose-induced glomerular mesangial cell hypertrophy.
  • DOI:
    10.1016/j.cellsig.2017.09.017
  • 发表时间:
    2018-01
  • 期刊:
  • 影响因子:
    4.8
  • 作者:
    Das F;Ghosh-Choudhury N;Kasinath BS;Choudhury GG
  • 通讯作者:
    Choudhury GG
Nox4 is a Target for Tuberin Deficiency Syndrome.
Nox4 是马铃薯球蛋白缺乏综合症的靶标。
  • DOI:
    10.1038/s41598-018-21838-4
  • 发表时间:
    2018
  • 期刊:
  • 影响因子:
    4.6
  • 作者:
    Shi,Qian;Viswanadhapalli,Suryavathi;Friedrichs,WilliamE;Velagapudi,Chakradhar;Szyndralewiez,Cédric;Bansal,Shweta;Bhat,ManzoorA;Choudhury,GoutamGhosh;Abboud,HannaE
  • 通讯作者:
    Abboud,HannaE
microRNA-181a downregulates deptor for TGFβ-induced glomerular mesangial cell hypertrophy and matrix protein expression.
  • DOI:
    10.1016/j.yexcr.2018.01.021
  • 发表时间:
    2018-03-01
  • 期刊:
  • 影响因子:
    3.7
  • 作者:
    Maity S;Bera A;Ghosh-Choudhury N;Das F;Kasinath BS;Choudhury GG
  • 通讯作者:
    Choudhury GG
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GOUTAM GHOSH CHOUDHURY其他文献

GOUTAM GHOSH CHOUDHURY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GOUTAM GHOSH CHOUDHURY', 18)}}的其他基金

BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10512762
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
  • 批准号:
    10364352
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    9269454
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    8398924
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Renal Cell Injury
肾细胞损伤的机制
  • 批准号:
    10013592
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Renal Cell Injury
肾细胞损伤的机制
  • 批准号:
    10554236
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    8696794
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    8043246
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanisms of Renal Cell Injury
肾细胞损伤的机制
  • 批准号:
    10293566
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Mechanism of Renal Cell Injury
肾细胞损伤机制
  • 批准号:
    8253501
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:

相似海外基金

Cannabis Legalization's Effects on Youth and Adult Nicotine and Tobacco Use
大麻合法化对青少年和成人尼古丁和烟草使用的影响
  • 批准号:
    10801535
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer
一项病例对照研究,评估广谱抗生素的使用和高出生体重作为早发性结直肠癌的潜在危险因素
  • 批准号:
    10687185
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
A Case-Control Study to Evaluate Broad-Spectrum Antibiotic use and High Birth Weight as Potential Risk Factors for Early-Onset Colorectal Cancer
一项病例对照研究,评估广谱抗生素的使用和高出生体重作为早发性结直肠癌的潜在危险因素
  • 批准号:
    10304590
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Mentoring in patient-oriented research on HIV and global health
指导以患者为中心的艾滋病毒和全球健康研究
  • 批准号:
    9889026
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Mentoring in patient-oriented research on HIV and global health
指导以患者为中心的艾滋病毒和全球健康研究
  • 批准号:
    9790038
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了